NHI coverage to extend for anti-cancer drugs from Sept.

Effective from Sept. 1, the NHI coverage will be extended to the anti-cancer drugs, anti-vomiting drugs and narcotic pain killers for cancer pains, including anastrozole (Amylidex tab.), capecitabine (Zeloda tab.) and enocitabine inj. (Sunlabine inj.).

In addition, the patient's pocket money for the medical charges will be reduced currently from 20-50% to 10% including some medications and t...